BET inhibition induces GDH1-dependent glutamine metabolic remodeling and vulnerability in liver cancer

Abstract

Bromodomain and extra-terminal domain (BET) proteins, which function partly through MYC proto-oncogene (MYC), are critical epigenetic readers and emerging therapeutic targets in cancer. Whether and how BET inhibition simultaneously induces metabolic remodeling in cancer cells remains unclear. Here we find that even transient BET inhibition by JQ-1 and other pan-BET inhibitors (pan-BETis) blunts liver cancer cell proliferation and tumor growth. BET inhibition decreases glycolytic gene expression but enhances mitochondrial glucose and glutamine oxidative metabolism revealed by metabolomics and isotope labeling analysis. Specifically, BET inhibition downregulates miR-30a to upregulate glutamate dehydrogenase 1 (GDH1) independent of MYC, which produces α- ketoglutarate for mitochondrial oxidative phosphorylation (OXPHOS). Targeting GDH1 or OXPHOS is synthetic lethal to BET inhibition, and combined BET and OXPHOS inhibition therapeutically prevents liver tumor growth in vitro and in vivo. Together, we uncover an important epigenetic-metabolic crosstalk whereby BET inhibition induces MYC-independent and GDH1-dependent glutamine metabolic remodeling that can be exploited for innovative combination therapy of liver cancer.

Keywords

BET / glutamate dehydrogenase 1 / oxidative phosphorylation / glutamine metabolism / synthetic lethality

References

[1] Llovet JM, Kelley RK, Villanueva A et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7:6.

[2] Villanueva A. Hepatocellular carcinoma. N Engl J Med 2019;380:1450–62.

[3] Siegel RL, Miller KD, Fuchs HE et al. Cancer statistics, 2021. CA Cancer J Clin 2021;71:7–33.

[4] Cancer Genome Atlas Research Network. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell 2017;169:1327–41.e23.

[5] Finn RS, Qin S, Ikeda M et al. Atezolizumab plus bevacizumabin unresectable hepatocellular carcinoma. N Engl J Med 2020;382:1894–905.

[6] Kudo M, Finn RS, Qin S et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391:1163–73.

[7] Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and cancer progression. Science 2020;368:eaaw5473.

[8] DeBerardinis RJ, Chandel NS. We need to talk about the Warburg effect. Nat Metab 2020;2:127–9.

[9] Pavlova NN, Zhu J, Thompson CB. The hallmarks of cancer metabolism: still emerging. Cell Metab 2022;34:355–77.

[10] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646–74.

[11] Satriano L, Lewinska M, Rodrigues PM et al. Metabolic rearrangements in primary liver cancers: cause and consequences. Nat Rev Gastroenterol Hepatol 2019;16:748–66.

[12] Adebayo Michael AO, Ko S, Tao J et al. Inhibiting glutamine-dependent mTORC1 activation ameliorates liver cancers driven by β-catenin mutations. Cell Metab 2019;29:1135–50.e6.

[13] Moon SH, Huang CH, Houlihan SL et al. p53 represses themevalonate pathway to mediate tumor suppression. Cell 2019;176:564–80.e19.

[14] Missiaen R, Anderson NM, Kim LC et al. GCN2 inhibition sensitizes arginine-deprived hepatocellular carcinoma cells to senolytic treatment. Cell Metab 2022;34:1151–67.e7.

[15] Rabinovich S, Adler L, Yizhak K et al. Diversion of aspartate in ASS1-deficient tumours fosters de novo pyrimidine synthesis. Nature 2015;527:379–83.

[16] Liu Z, You Y, Chen Q et al. Extracellular vesicle-mediated communication between hepatocytes and natural killer cells promotes hepatocellular tumorigenesis. Mol Ther 2022;30:606–20.

[17] Li F, Huangyang P, Burrows M et al. FBP1 loss disrupts liver metabolism and promotes tumorigenesis through a hepatic stellate cell senescence secretome. Nat Cell Biol 2020;22:728–39.

[18] Wang N, Wu R, Tang D et al. The BET family in immunity and disease. Signal Transduct Target Ther 2021;6:23.

[19] Stine ZE, Walton ZE, Altman BJ et al. MYC, metabolism, and cancer. Cancer Discov 2015;5:1024–39.

[20] Dong Y, Tu R, Liu H et al. Regulation of cancer cell metabolism: oncogenic MYC in the driver’s seat. Signal Transduct Target Ther 2020;5:124.

[21] Shu S, Lin CY, He HH et al. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature 2016;529:413–7.

[22] Asangani IA, Dommeti VL, Wang X et al. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 2014;510:278–82.

[23] Ding N, Hah N, Yu RT et al. BRD4 is a novel therapeutic target for liver fibrosis. Proc Natl Acad Sci U S A 2015;112:15713–8.

[24] Jühling F, Hamdane N, Crouchet E et al. Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma. Gut 2021;70:157–69.

[25] Shorstova T, Foulkes WD, Witcher M. Achieving clinical success with BET inhibitors as anti-cancer agents. Br J Cancer 2021;124:1478–90.

[26] Stathis A, Bertoni F. BET proteins as targets for anticancer treatment. Cancer Discov 2018;8:24–36.

[27] Delmore JE, Issa GC, Lemieux ME et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011;146:904–17.

[28] Piha-Paul SA, Sachdev JC, Barve M et al. First-in-human study of mivebresib (ABBV-075), an oral pan-inhibitor of bromodomain and extra terminal proteins, in patients with relapsed/refractory solid tumors. Clin Cancer Res 2019;25:6309–19.

[29] Wang Y, He L, Du Y et al. The long noncoding RNA lncTCF7 promotes self-renewal of human liver cancer stem cells through activation of Wnt signaling. Cell Stem Cell 2015;16:413–25.

[30] Gilan O, Rioja I, Knezevic K et al. Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation. Science 2020;368:387–94.

[31] Altman BJ, Stine ZE, Dang CV. From Krebs to clinic: glutaminemetabolism to cancer therapy. Nat Rev Cancer 2016;16:619–34.

[32] Fendt SM, Bell EL, Keibler MA et al. Reductive glutamine metabolism is a function of the α-ketoglutarate to citrate ratio in cells. Nat Commun 2013;4:2236.

[33] Jiang L, Shestov AA, Swain P et al. Reductive carboxylation supports redox homeostasis during anchorage-independent growth. Nature 2016;532:255–8.

[34] Wise DR, Ward PS, Shay JE et al. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability. Proc Natl Acad Sci U S A 2011;108:19611–6.

[35] Mullen AR, Wheaton WW, Jin ES et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 2011;481:385–8.

[36] Metallo CM, Gameiro PA, Bell EL et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 2011;481:380–4.

[37] Jin L, Li D, Alesi GN et al. Glutamate dehydrogenase 1 signals through antioxidant glutathione peroxidase 1 to regulate redox homeostasis and tumor growth. Cancer Cell 2015;27:257–70.

[38] Lee P, Malik D, Perkons N et al. Targeting glutamine metabolism slows soft tissue sarcoma growth. Nat Commun 2020;11:498.

[39] Mertz JA, Conery AR, Bryant BM et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A 2011;108:16669–74.

[40] Molina JR, Sun Y, Protopopova M et al. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat Med 2018;24:1036–46.

[41] Wang C, Vegna S, Jin H et al. Inducing and exploiting vulnerabilities for the treatment of liver cancer. Nature 2019;574:268–72.

[42] Nguyen TTT, Zhang Y, Shang E et al. HDAC inhibitors elicit metabolic reprogramming by targeting super-enhancers in glioblastoma models. J Clin Invest 2020;130:3699–716.

[43] Jin L, Chun J, Pan C et al. The PLAG1-GDH1 axis promotes anoikis resistance and tumor metastasis through CamKK2-AMPK signaling in LKB1-deficient lung cancer. Mol Cell 2018;69:87–99.e7.

[44] Yang C, Sudderth J, Dang T et al. Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res 2009;69:7986–93.

[45] Coloff JL, Murphy JP, Braun CR et al. Differential glutamate metabolism in proliferating and quiescent mammary epithelial cells. Cell Metab 2016;23:867–80.

[46] Yap TA, Daver N, Mahendra M et al. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med 2023;29:115–26.

[47] Gopal RK, Vantaku VR, Panda A et al. Effectors enabling adaptation to mitochondrial complex I loss in Hürthle cell carcinoma. Cancer Discov 2023;13:1904–21.

[48] Frank AR, Li V, Shelton SD et al. Mitochondrial-encoded complex I impairment induces a targetable dependency on aerobic fermentation in Hürthle cell carcinoma of the thyroid. Cancer Discov 2023;13:1884–903.

[49] Su X, Lu W, Rabinowitz JD. Metabolite spectral accuracy on orbitraps. Anal Chem 2017;89:5940–8.

[50] Subramanian A, Tamayo P, Mootha VK et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545–50.

RIGHTS & PERMISSIONS

2024 The Author(s) 2024. Published by Oxford University Press on behalf of Higher Education Press.